Antifibrinolytics: stabilise fibrin clots when excessive fibrinolysis is causing harm
Antifibrinolytic medicines reduce fibrin breakdown by inhibiting plasminogen activation or plasmin activity. They stabilise haemostatic clots; they do not replace resuscitation, source control, blood products, uterotonics or surgery when these are required. Correct indication, timing, thrombosis risk and renal function determine safe use.
Safety first
In major trauma and postpartum haemorrhage (PPH), tranexamic acid is time-critical and adjunctive. Activate the emergency/major-haemorrhage pathway, treat the bleeding source and follow the current local protocol. Do not use a general learning page to choose emergency doses.
Lesson map
Preserve fibrin by limiting plasmin activity.
Tranexamic acid, aminocaproic acid, aprotinin.
PPH, trauma, surgery and heavy menstrual bleeding.
Thrombosis, renal impairment, seizures and haematuria.
1. Fibrinolysis and the drug target
After a fibrin clot has achieved haemostasis, tissue plasminogen activator (tPA) and urokinase convert plasminogen to plasmin. Plasmin degrades fibrin into soluble degradation products. This normal process limits unnecessary clot persistence; it becomes harmful when premature or excessive fibrinolysis worsens bleeding.
| Component | Function | Drug relevance |
|---|---|---|
| tPA/uPA | Activate plasminogen. | TXA and aminocaproic acid competitively reduce plasminogen binding/activation at fibrin. |
| Plasmin | Breaks down fibrin and, systemically, can reduce fibrinogen. | Inhibition preserves clot stability when clinically appropriate. |
| PAI and α2-antiplasmin | Natural inhibitors of fibrinolysis. | Antifibrinolytics reinforce this direction; excessive treatment may favour thrombosis. |
2. Classification and pharmacology
| Medicine | Mechanism | Key point |
|---|---|---|
| Tranexamic acid (TXA) | Synthetic lysine analogue; blocks lysine-binding sites on plasminogen/plasmin and reduces fibrin breakdown. | Main commonly used agent; oral and IV pathways differ. Renal excretion means protocol-led dose adjustment in renal impairment. |
| Aminocaproic acid | Lysine analogue with similar inhibition of plasminogen activation/fibrin binding. | Used in selected specialist perioperative/haematology settings. |
| Aprotinin | Serine protease inhibitor that inhibits plasmin and other proteases. | Restricted/specialist use; not a routine first-line substitute for TXA. |
3. Clinical indications
| Situation | Role | Clinical rule |
|---|---|---|
| PPH | Early IV TXA is part of WHO-recommended care for clinically diagnosed PPH, ideally within 3 hours of birth. | Give alongside uterine massage, uterotonics, IV fluids, examination/source control and escalation. |
| Major trauma with significant bleeding | Early TXA may reduce bleeding-related mortality in protocolled trauma care. | Record injury time and manage ABCDE/major haemorrhage; TXA is adjunctive to blood products and surgery. |
| Surgery | May reduce perioperative blood loss/transfusion in selected operations. | Use surgical/anaesthetic protocol and review thrombosis history and renal function. |
| Heavy menstrual bleeding | Oral TXA is a non-hormonal option for some patients. | Assess pregnancy, anaemia and cause of bleeding; consider personal thrombosis risk. |
| Haemophilia/dental or mucosal bleeding | Adjunct to factor replacement and local measures in selected pathways. | Follow haematology/dental protocol. |
4. Pre-treatment checklist
- Confirm the bleeding source and whether excessive fibrinolysis is plausible.
- For trauma/PPH, identify onset time and start definitive bleeding management immediately.
- Ask about DVT/PE/arterial thrombosis, thrombophilia, seizures, renal disease and allergy.
- Review anticoagulants, antiplatelets and other pro-thrombotic medicines.
- Check renal function and, in major bleeding, FBC/coagulation/fibrinogen and group-and-save/crossmatch as the protocol directs.
- In haematuria, seek senior/urology advice: clots can obstruct the urinary tract, especially with upper-tract bleeding.
5. Contraindications, cautions and adverse effects
Haemostasis is not the same as thrombosis
Avoid or seek specialist direction in active thromboembolic disease, uncontrolled DIC, significant renal impairment, unexplained upper urinary-tract haematuria and situations where clot extension could cause harm. Exact exclusions vary by product and indication.
- Thromboembolism: assess new unilateral leg swelling, pleuritic chest pain, sudden dyspnoea and focal neurological symptoms.
- Renal impairment: accumulation can raise adverse-effect risk; adjust treatment by protocol.
- Seizures: particularly reported with high-dose IV surgical use; monitor neurological status in high-risk settings.
- Visual symptoms: altered colour vision or visual disturbance requires prompt assessment.
- Common effects: nausea, vomiting, diarrhoea, dizziness and headache.
6. Monitoring and counselling
- In acute bleeding, monitor pulse, BP, ongoing blood loss, urine output, mental state and response to definitive treatment.
- Trend FBC, coagulation/fibrinogen and renal function as directed; a laboratory value alone does not prove haemostasis.
- Administer IV TXA at the prescribed rate; rapid administration can cause hypotension.
- For heavy periods, explain that TXA reduces bleeding but does not remove the underlying cause.
- Seek urgent help for chest pain, dyspnoea, new leg swelling, focal neurological symptoms, visual disturbance or persistent/severe bleeding.
7. Antifibrinolytics versus thrombolytics
| Feature | Thrombolytics | Antifibrinolytics |
|---|---|---|
| Action | Activate plasmin and dissolve fibrin clot. | Inhibit plasminogen/plasmin action and preserve fibrin. |
| Typical emergency role | Selected STEMI, ischaemic stroke, massive PE. | PPH, trauma, surgical/mucosal bleeding reduction. |
| Main danger | Major bleeding/intracranial haemorrhage. | Potential thrombosis or inappropriate clot persistence. |
High-yield cases and OSCE points
Call for help, commence the full first-response bundle and give protocolled early TXA without delaying source control.
Record injury time; manage ABCDE and major haemorrhage. TXA is time-sensitive and adjunctive.
Do not issue TXA casually; assess thrombosis history and obtain prescriber review.
Identify source and escalate rather than routinely giving an antifibrinolytic.
- Define antifibrinolytic and name TXA as the common lysine analogue.
- State the WHO PPH principle: early IV TXA within 3 hours of birth, alongside standard care.
- List thrombosis risk, renal impairment, seizures, visual symptoms and haematuria as core safety checks.
Further study
Course reference: Fibrinolytics and Antifibrinolytics—SlideShare. Review the WHO PPH TXA recommendation, NICE heavy menstrual bleeding guidance and MedlinePlus TXA safety information. Local protocols determine emergency dose, route and exclusions.
